**CALDOLOR**

**INDICATIONS AND USAGE**

**Analgesia (Pain)**

Caldolor is indicated in adults for the management of mild to moderate pain and the management of moderate to severe pain as an adjunct to opioid analgesics.

**Antipyretic (Fever)**

Caldolor is indicated for the reduction of fever in adults.

**LIMITATIONS ON DOSING**

Do not exceed 3200 mg total daily dose.

---

**KETOROLAC**

**INDICATIONS AND USAGE**

Ketorolac is indicated for the short-term (≤ 5 days) management of moderately severe acute pain that requires analgesia at the opioid level, usually in a postoperative setting.

**LIMITATIONS ON DOSING**

The combined duration of use of Ketorolac Injection and Ketorolac Tablets is not to exceed five (5) days. The use of Ketorolac Tablets is only indicated as continuation therapy to Ketorolac Injection.

---

**WARNING**

Ketorolac tromethamine, a nonsteroidal anti-inflammatory drug (NSAID), is indicated for the short-term (≤ 5 days in adults) management of moderately severe acute pain that requires analgesia at the opioid level. It is NOT indicated for severe or chronic painful conditions. Ketorolac tromethamine is a potent NSAID analgesic, and its administration carries many risks. The resulting NSAID-related adverse events can be serious in certain patients for whom ketorolac tromethamine is indicated, especially when the drug is used inappropriately. Increasing the dose of ketorolac tromethamine beyond the label recommendations will not provide better efficacy but will result in increasing the risk of developing serious adverse events.

**Gastrointestinal Risk**

- NSAIDs increase the risk of serious gastrointestinal (GI) adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients are at greater risk for serious gastrointestinal events (see Warnings and Precautions (5.2)).

**Cardiovascular Risk**

- Non-steroidal anti-inflammatory drugs (NSAIDs) may increase the risk of serious cardiovascular (CV) thrombotic events, myocardial infarction, and stroke, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk (see Warnings and Precautions (5.1)).

**INDICATIONS AND USAGE**

Ketorolac tromethamine is indicated for the management of moderate to severe pain as an adjunct to opioid analgesics.

**Analgesia (Pain)**

Caldolor is indicated in adults for the management of mild to moderate pain and the management of moderate to severe pain as an adjunct to opioid analgesics.

**Antipyretic (Fever)**

Caldolor is indicated for the reduction of fever in adults.

**LIMITATIONS ON DOSING**

Do not exceed 3200 mg total daily dose.
**Not All NSAIDs Are The Same**

**CALDOLOR** is the only IV agent indicated for the treatment of pain and fever.

**IMPORTANT SAFETY INFORMATION**

CALDOLOR should be used with caution in patients with congestive heart failure, kidney impairment, at risk of blood clots, and in those who have a history of ulcers or gastrointestinal bleeding. When used in such patients, attention to using the lowest effective dose for the shortest time period is important to reduce the risk of serious adverse events. Ibuprofen has been associated with high blood pressure, serious skin reactions, and serious allergic reactions.

The most common adverse events reported in the controlled clinical trials were nausea, flatulence, vomiting, and headache.

Please see full Prescribing Information, including Boxed Warning.

CALDOLOR is a registered trademark of Cumberland Pharmaceuticals Inc.


For sales representative use only. Not to be left with healthcare professionals.